Rua Bioscience Limited — Major Shareholding Notification 2021

Jun 8, 2021

Disclosure of movement of 1% or more in substantial holding or change in nature of relevant interest, or both

Sections 277 and 278, Financial Markets Conduct Act 2013

To NZX Limited ( NZX ) and

To Rua Bioscience Limited ( Rua )

Relevant event being disclosed: Movement of 1% or more in the substantial holding

Date of relevant event: 4 June 2021 Date this disclosure made: 8 June 2021 Date last disclosure made: 22 October 2020

Substantial product holder(s) giving disclosure

Full name(s): Hikurangi Bioactives Limited Partnership ( HBLP ) and Hikurangi Bioactives GP Limited ( HBGPL )

Summary of substantial holding

Class of quoted voting products: ordinary shares in Rua

Summary for HBLP and HBGPL

For this disclosure,—

• (a) total number held in class: 17,616,591

• (b) total in class: 140,262,591

• (c) total percentage held in class: 12.58%

• For last disclosure,—

• (a) total number held in class: 23,488,787

• (b) total in class: 140,012,225

• (c) total percentage held in class: 16.776 %

Details of transactions and events giving rise to relevant event

Details of the transactions or other events requiring disclosure:

• The dates of the beginning and end of the period of the aggregated on market and off market trades are 19 March 2021 and 4 June 2021.

• The nature of the transactions is on-market and off-market sale of the shares.

• The total consideration received for aggregated on-market trades is NZ$568,740.80 (before fees) for 1,380,000 ordinary shares in Rua.

1

• The total consideration received for aggregated off-market trades is NZ$1,662,112.00 (before fees) for 4,492,196 ordinary shares in Rua.

• The total number of ordinary shares in Rua to which the aggregated on-market and off-market trades related is 5,872,196.

Details after relevant event

Details for HBLP

Nature of relevant interest(s): Registered holder and beneficial owner of the shares

For that relevant interest,—

• (a) number held in class: 17,616,591

• (b) percentage held in class: 12.58%

• (c) current registered holder(s): HBLP

• (d) registered holder(s) once transfers are registered: unknown

• For a derivative relevant interest, also—

• (a) type of derivative: Not applicable

• (b) details of derivative: Not applicable

• (c) parties to the derivative: Not applicable

• (d) if the substantial product holder is not a party to the derivative, the nature of the relevant interest in the derivative: Not applicable

Details for HBGPL

Nature of relevant interest(s): HBGPL has the responsibility, authority and power for the management and control of the business and affairs of HBLP as its general partner, and accordingly has a relevant interest in HBLP’s shares in Rua.

For that relevant interest,—

• (a) number held in class: 17,616,591

• (b) percentage held in class: 12.58%

• (c) current registered holder(s): HBLP

• (d) registered holder(s) once transfers are registered: unknown

• For a derivative relevant interest, also—

• (a) type of derivative: Not applicable

• (b) details of derivative: Not applicable

2

• (c) parties to the derivative: Not applicable

• (d) if the substantial product holder is not a party to the derivative, the nature of the relevant interest in the derivative: Not applicable

Additional information

Address(es) of substantial product holder(s):

• HBLP: 6434 Waiapu Road, Rd 1, Ruatoria, 4081, New Zealand

• HBGPL: c/o Coates Associates Limited, 300 Childers Road, Gisborne, Gisborne, 4010, New Zealand

Contact details: Damian Skinner, damian@hikurangibioactives.co.nz, Tel. 021526870

Nature of connection between substantial product holders: HBLP and HBGPL are associated persons under section 12(1) of the Financial Markets Conduct Act 2013.

Name of any other person believed to have given, or believed to be required to give, a disclosure under the Financial Markets Conduct Act 2013 in relation to the financial products to which this disclosure relates: Manu Caddie

Certification

I, Damian Hugh Skinner, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

3